Date | Time | Source | Headline | Symbol | Company |
07/19/2024 | 5:03PM | Edgar (US Regulatory) | Form S-4/A - Registration of securities, business combinations: [Amend] | NASDAQ:KTRA | Kintara Therapeutics Inc |
07/12/2024 | 5:17PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:KTRA | Kintara Therapeutics Inc |
07/08/2024 | 6:45AM | Edgar (US Regulatory) | Form 425 - Prospectuses and communications, business combinations | NASDAQ:KTRA | Kintara Therapeutics Inc |
07/08/2024 | 6:40AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:KTRA | Kintara Therapeutics Inc |
07/08/2024 | 6:30AM | PR Newswire (US) | TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor | NASDAQ:KTRA | Kintara Therapeutics Inc |
07/01/2024 | 8:35AM | PR Newswire (US) | Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones | NASDAQ:KTRA | Kintara Therapeutics Inc |
06/13/2024 | 4:10PM | Edgar (US Regulatory) | Form 425 - Prospectuses and communications, business combinations | NASDAQ:KTRA | Kintara Therapeutics Inc |
06/13/2024 | 4:05PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:KTRA | Kintara Therapeutics Inc |
06/03/2024 | 8:50AM | Edgar (US Regulatory) | Form 425 - Prospectuses and communications, business combinations | NASDAQ:KTRA | Kintara Therapeutics Inc |
06/03/2024 | 8:45AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:KTRA | Kintara Therapeutics Inc |
06/03/2024 | 8:35AM | PR Newswire (US) | TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC) | NASDAQ:KTRA | Kintara Therapeutics Inc |
05/17/2024 | 4:10PM | Edgar (US Regulatory) | Form ARS - Annual Report to Security Holders | NASDAQ:KTRA | Kintara Therapeutics Inc |
05/17/2024 | 4:05PM | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements | NASDAQ:KTRA | Kintara Therapeutics Inc |
05/14/2024 | 4:55PM | Edgar (US Regulatory) | Form 425 - Prospectuses and communications, business combinations | NASDAQ:KTRA | Kintara Therapeutics Inc |
05/14/2024 | 4:50PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:KTRA | Kintara Therapeutics Inc |
05/14/2024 | 4:45PM | PR Newswire (US) | Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results | NASDAQ:KTRA | Kintara Therapeutics Inc |
05/14/2024 | 4:40PM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:KTRA | Kintara Therapeutics Inc |
05/13/2024 | 4:06PM | Edgar (US Regulatory) | Form S-4 - Registration of securities, business combinations | NASDAQ:KTRA | Kintara Therapeutics Inc |
04/05/2024 | 1:09PM | PR Newswire (US) | Kuehn Law Encourages KTRA, ABIO, SWAV, and NS Investors to Contact Law Firm | NASDAQ:KTRA | Kintara Therapeutics Inc |
04/03/2024 | 7:00AM | PR Newswire (US) | Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement | NASDAQ:KTRA | Kintara Therapeutics Inc |
03/27/2024 | 9:00AM | PR Newswire (US) | Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab | NASDAQ:KTRA | Kintara Therapeutics Inc |
02/27/2024 | 6:59AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:KTRA | Kintara Therapeutics Inc |
02/26/2024 | 7:00AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:KTRA | Kintara Therapeutics Inc |
02/22/2024 | 7:00AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:KTRA | Kintara Therapeutics Inc |
02/14/2024 | 4:07PM | PR Newswire (US) | Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate Update | NASDAQ:KTRA | Kintara Therapeutics Inc |
02/12/2024 | 9:05AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:KTRA | Kintara Therapeutics Inc |
02/12/2024 | 9:00AM | PR Newswire (US) | Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer | NASDAQ:KTRA | Kintara Therapeutics Inc |
12/18/2023 | 4:10PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:KTRA | Kintara Therapeutics Inc |
12/18/2023 | 4:05PM | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:KTRA | Kintara Therapeutics Inc |
12/15/2023 | 4:15PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:KTRA | Kintara Therapeutics Inc |